CV6-168

CV6-168 is a first-in-class, targeted small molecule inhibitor that specifically targets the enzyme deoxyuridine triphosphatase (dUTPase). By inhibiting dUTPase, CV6-168 induces misincorporation of uracil into DNA when used in combination with thymidylate synthase inhibitors such as 5-fluorouracil (5-FU), leading to increased DNA damage and cell death in cancer cells. This mechanism also activates immune stimulatory pathways. Unlike some other agents, CV6-168 does not inhibit dihydropyrimidine dehydrogenase, thereby avoiding drug-drug interactions with fluoropyrimidines and complex dose modifications. It is being developed for use in combination with standard anti-cancer therapies for the treatment of multiple high-incidence cancers and is currently undergoing Phase 1a clinical trials in patients with advanced solid tumors refractory to standard treatments[1][2][4][5].